Ribbon Acquisition Corp.
RIBBU
NASDAQ Capital Market10.48
USD
+0.99
- -
CIK
0002035016
ISIN
KYG7552W1252
CUSIP
G7552W125
Return %
Stock
S&P500
1Y
3.56
26.53
3Y
4.70
76.60
5Y
4.70
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Angshuman Ghosh
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Central Park Tower La Tour Shinjuku, Room 3001, 6-15-1 Nishishinjuku Tokyo Japan 160-0023
- IPO Date
- Jan 15, 2025
- CIK
- 0002035016
- Website
- ribbonacquisitioncorp.com
- Similar Companies
- Business
- Ribbon Acquisition Corp. (RIBBU) serves as a blank check company whose principal business activity involves pursuing a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar initial business combination with one or more unidentified businesses. Incorporated in the Cayman Islands in 2024 and headquartered at Central Park Tower LaTour Shinjuku Room 3001, 6-15-1 Nishi Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan, the company currently maintains no significant operations of its own; instead, it holds cash proceeds primarily from its January 2025 initial public offering of 5 million units at $10 each, raising $50 million, with each unit comprising one Class A ordinary share and one right convertible into one-seventh of one Class A ordinary share upon a successful business combination. The company targets opportunities globally, particularly in sectors such as healthcare, with a focus on entities in Asia. In June 2025, Ribbon Acquisition Corp. entered into a definitive business combination agreement with DRC Medicine Ltd., a Tokyo-based biotechnology firm specializing in the design and manufacture of AI-powered allergy and infection diagnostic kits and protective face masks, alongside DRC Medicine Inc. (PubCo) and DRC Merger Inc.; the proposed transaction, implying a pre-money equity value of $350 million for DRC Medicine and an aggregate enterprise value of approximately $422.15 million, contemplates a domestication of Ribbon from the Cayman Islands to Delaware, followed by a merger into a subsidiary of PubCo, subject to shareholder approval, regulatory clearances, Nasdaq listing of PubCo common stock, and other customary closing conditions, with a registration statement on Form S-4 expected to be filed promptly thereafter. The company announced separate trading of its ordinary shares and rights in recent updates, maintains a 12-month tenor for its initial business combination, and lists its units (RIBBU), Class A ordinary shares (RIBB), and rights (RIBBR) on the Nasdaq Stock Market.